DK2830662T3 - Fremgangsmåder til behandlng af hårtabsforstyrrelser - Google Patents

Fremgangsmåder til behandlng af hårtabsforstyrrelser Download PDF

Info

Publication number
DK2830662T3
DK2830662T3 DK13769804.9T DK13769804T DK2830662T3 DK 2830662 T3 DK2830662 T3 DK 2830662T3 DK 13769804 T DK13769804 T DK 13769804T DK 2830662 T3 DK2830662 T3 DK 2830662T3
Authority
DK
Denmark
Prior art keywords
treatment
methods
hair loss
loss disorders
disorders
Prior art date
Application number
DK13769804.9T
Other languages
English (en)
Inventor
Angela M Christiano
Raphael Clynes
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Application granted granted Critical
Publication of DK2830662T3 publication Critical patent/DK2830662T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK13769804.9T 2012-03-29 2013-03-29 Fremgangsmåder til behandlng af hårtabsforstyrrelser DK2830662T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261617225P 2012-03-29 2012-03-29
US201261645499P 2012-05-10 2012-05-10
PCT/US2013/034688 WO2013149194A1 (en) 2012-03-29 2013-03-29 Methods for treating hair loss disorders

Publications (1)

Publication Number Publication Date
DK2830662T3 true DK2830662T3 (da) 2019-01-02

Family

ID=49261311

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13769804.9T DK2830662T3 (da) 2012-03-29 2013-03-29 Fremgangsmåder til behandlng af hårtabsforstyrrelser

Country Status (12)

Country Link
EP (2) EP2830662B1 (da)
JP (2) JP6212107B2 (da)
KR (1) KR102135601B1 (da)
CN (1) CN104334191A (da)
DK (1) DK2830662T3 (da)
ES (1) ES2694681T3 (da)
HR (1) HRP20181976T1 (da)
HU (1) HUE040127T2 (da)
PL (1) PL2830662T3 (da)
PT (1) PT2830662T (da)
SI (1) SI2830662T1 (da)
WO (1) WO2013149194A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016259023A1 (en) * 2015-05-07 2017-11-30 The Trustees Of Columbia University In The City Of New York Methods and compositions for promoting hair growth
CN104789689B (zh) * 2015-05-13 2018-10-02 北京泱深生物信息技术有限公司 作为肺腺癌诊治靶标的clec9a基因
AU2016328764B2 (en) 2015-09-25 2020-07-09 Dizal (Jiangsu) Pharmaceutical Co., Limited Compounds and methods for inhibiting JAK
KR20170101724A (ko) * 2016-02-29 2017-09-06 양지화학 주식회사 야누스인산화효소 억제제로서의 치환된 N-(피롤리딘-3-일)-7H-피롤로[2,3-d]피리미딘-4-아민의 용도
CN105695617A (zh) * 2016-04-22 2016-06-22 王冬国 ***状癌的肿瘤标志物及其应用
EP3452039B1 (en) 2016-05-04 2024-07-03 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
CN114176043B (zh) * 2016-06-14 2024-04-23 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
KR101657082B1 (ko) * 2016-08-08 2016-09-13 에스씨엠생명과학 주식회사 CXCL1(chemokine (C-X-C motif) ligand 1) 단백질을 유효성분으로 포함하는 탈모 예방 또는 치료용 약학적 조성물
WO2018087202A1 (en) * 2016-11-10 2018-05-17 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
BR112020002265A2 (pt) 2017-08-01 2020-07-28 Theravance Biopharma R&D Ip, Llc compostos pirazólicos e triazólicos bicíclicos como inibidores de jak quiinase
WO2019094798A1 (en) 2017-11-10 2019-05-16 The Trustees Of Columbia University In The City Of New York Methods and compositions for promoting or inducing hair growth
EP3810144A4 (en) * 2018-06-04 2022-08-17 Chemistryrx TOPICAL HAIR GROWTH STIMULATING COMPOSITIONS
CN113498352A (zh) 2019-01-23 2021-10-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-***并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪
CN113853443A (zh) * 2019-03-08 2021-12-28 株式会社Neogentc 用于预测淋巴细胞的肿瘤反应性的标志物及其用途
CN111041095B (zh) * 2019-07-11 2021-11-30 江苏医药职业学院 检测8号染色体开放阅读框73表达水平的试剂的应用和试剂盒
KR102187371B1 (ko) * 2019-08-02 2020-12-04 연세대학교 산학협력단 FoxQ1 유전자가 과발현된 지방유래 줄기세포 및 이의 용도
EP4054527A4 (en) * 2019-11-08 2023-12-06 Cage Bio Inc. TOPICAL ADMINISTRATION OF TOFACITINIB USING AN IONIC LIQUID
CN114901659A (zh) 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的稠合嘧啶吡啶酮化合物
EP4149412A1 (en) * 2020-05-12 2023-03-22 Chemistryrx Compositions for treating hair loss
FR3111917A1 (fr) * 2020-06-30 2021-12-31 L'oreal Signature moléculaire d’un état alopécique commun, associée aux jonctions cellulaires
TW202345824A (zh) * 2022-03-18 2023-12-01 大陸商四川科倫博泰生物醫藥股份有限公司 氮雜環丁烷衍生物的用途及治療方法
CN114870016B (zh) * 2022-04-21 2023-05-26 上海博悦生物科技有限公司 一种jak抑制剂的微乳泡沫剂及其应用
CN115137832B (zh) * 2022-07-07 2023-11-17 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 一种jak抑制剂的用途及其抗毛霉感染实验方法
FR3143040A1 (fr) * 2022-12-12 2024-06-14 L'oreal Méthode de pronostic et/ou de diagnostic d’une perte de densité capillaire

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5879680A (en) 1987-12-23 1999-03-09 The United States Of America As Represented By The Department Of Health And Human Services Cloned DNA for synthesizing unique glucocerebrosidase
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US6451600B1 (en) 1989-12-22 2002-09-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
DK0494955T3 (da) 1989-10-05 1998-10-26 Optein Inc Cellefri syntese og isolering af hidtil ukendte gener og polypeptider
PT96059B (pt) 1989-12-04 1998-07-31 Searle & Co Sistema de camada unica para a administracao de um medicamento por via transdermica
US5747334A (en) 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
CA2108144A1 (en) 1991-03-06 1992-09-07 Jack A. Roth Methods and compositions for the selective inhibition of gene expression
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
CA2123809A1 (en) 1991-12-18 1993-06-24 Debra L. Wilfong Multilayered barrier structures
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
JPH09507487A (ja) 1994-01-05 1997-07-29 アーキュール，インコーポレーテッド 選ばれた性質を有するアミンイミドおよびオキサゾロンをベースとした分子の系統的モジュール製造
US5705625A (en) * 1994-12-15 1998-01-06 The Johns Hopkins University School Of Medicine Nucleic Acid Encoding novel protein tyrosine kinase
US5712171A (en) 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array
SK70598A3 (en) 1995-11-30 1999-04-13 Univ Texas Methods and compositions for the diagnosis and treatment of cancer
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
GB9623833D0 (en) 1996-11-16 1997-01-08 Zeneca Ltd Chemical compound
US7419661B2 (en) 1997-04-30 2008-09-02 The Centre Of Excellence For Life Sciences Limited Dermal sheath tissue in wound healing
AR013269A1 (es) 1997-08-04 2000-12-13 Scras Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral
US6210666B1 (en) 1997-10-21 2001-04-03 Orphan Medical, Inc. Truncated α-galactosidase A to treat fabry disease
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
WO2000000202A1 (en) * 1998-06-30 2000-01-06 Parker Hughes Institute Method for inhibiting c-jun expression using jak-3 inhibitors
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
WO2000044914A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
DE60017115T2 (de) * 1999-02-10 2005-12-08 Mitsubishi Pharma Corp. Amid-derivate und deren medizinische verwendung
AU1086501A (en) 1999-10-15 2001-04-30 Carnegie Institution Of Washington Rna interference pathway genes as tools for targeted genetic interference
GB9925964D0 (en) 1999-11-03 1999-12-29 Jahoda Colin A B Hair transplantation
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US6188045B1 (en) 2000-04-03 2001-02-13 Alto-Shaam, Inc. Combination oven with three-stage water atomizer
EP1148185B1 (en) 2000-04-20 2003-12-03 McNamara, Bernard A swimming pool assembly
US20020173478A1 (en) 2000-11-14 2002-11-21 The Trustees Of The University Of Pennsylvania Post-transcriptional gene silencing by RNAi in mammalian cells
US7294504B1 (en) 2001-12-27 2007-11-13 Allele Biotechnology & Pharmaceuticals, Inc. Methods and compositions for DNA mediated gene silencing
KR20050013562A (ko) * 2002-05-30 2005-02-04 버텍스 파마슈티칼스 인코포레이티드 Ｊａｋ 및 ｃｄｋ2 프로테인 키나아제의 억제제
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
CA2958146C (en) 2002-11-14 2019-08-20 Aderans Research Institute, Inc. Cultivation of hair inductive cells
US7884189B2 (en) 2003-01-10 2011-02-08 The Trustees Of Columbia University In The City Of New York Carboxyltransferase domain of acetyl-CoA carboxylase
CA2563569A1 (en) * 2004-05-03 2005-11-10 Novartis Ag Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor
WO2006119365A2 (en) 2005-05-02 2006-11-09 Cold Spring Harbor Laboratory Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
WO2007059010A2 (en) 2005-11-14 2007-05-24 Enterprise Partners Venture Capital Stem cell factor therapy for tissue injury
DE602006019916D1 (de) 2005-12-12 2011-03-10 Canji Inc Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase
AU2007207533B8 (en) * 2006-01-17 2012-06-28 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of Janus kinases
WO2007100870A2 (en) 2006-02-28 2007-09-07 The Trustees Of Columbia University In The City Of New York Methods for compact aggregation of dermal cells
AU2007220047B2 (en) * 2006-02-28 2013-08-01 Ym Biosciences Australia Pty Ltd Inhibition of JAK2 as a treatment of pulmonary arterial hypertension
GB0605691D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
US7704533B2 (en) * 2006-12-13 2010-04-27 J&J Consumer Companies, Inc. Compositions and methods of inducing hair growth utilizing Continus coggygria
EP2274288A2 (en) * 2008-04-24 2011-01-19 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
WO2010093808A1 (en) * 2009-02-11 2010-08-19 Reaction Biology Corp. Selective kinase inhibitors
DK2635299T3 (da) * 2010-11-02 2019-10-21 Univ Columbia Fremgangsmåder til behandling af hårtabsforstyrrelser

Also Published As

Publication number Publication date
SI2830662T1 (sl) 2019-01-31
EP2830662B1 (en) 2018-08-29
JP2018027959A (ja) 2018-02-22
HRP20181976T1 (hr) 2019-01-25
HUE040127T2 (hu) 2019-02-28
ES2694681T3 (es) 2018-12-26
CN104334191A (zh) 2015-02-04
PL2830662T3 (pl) 2019-02-28
EP3459565A1 (en) 2019-03-27
JP6527565B2 (ja) 2019-06-05
WO2013149194A1 (en) 2013-10-03
KR20140148459A (ko) 2014-12-31
KR102135601B1 (ko) 2020-07-20
JP6212107B2 (ja) 2017-10-11
EP2830662A4 (en) 2015-09-09
EP2830662A1 (en) 2015-02-04
JP2015515470A (ja) 2015-05-28
PT2830662T (pt) 2018-11-29

Similar Documents

Publication Publication Date Title
DK2830662T3 (da) Fremgangsmåder til behandlng af hårtabsforstyrrelser
DK2635299T3 (da) Fremgangsmåder til behandling af hårtabsforstyrrelser
DK2983787T3 (da) Fremgangsmåde til behandling af posttraumatisk stresssygdom
DK2906696T4 (da) Fremgangsmåder til modulering af c9orf72-ekspression
DK2968208T3 (da) Behandling af kataplexi
DK2919796T3 (da) Brug af akkermansia til behandling af stofskiftesygdomme
DK2897620T3 (da) Fremgangsmåde til behandling af cancer
DK2885010T3 (da) Fremgangsmåder til behandling med tauopati
DK2895156T3 (da) Fremgangsmåde til fremstilling af terapeutiske nanopartikler
DK3811943T3 (da) Forbindelse til anvendelse til behandling af øjenlidelser
DK3329884T3 (da) Implanterbar indretning til behandling af glaukom
DK2846809T3 (da) Behandling af myelosuppression
DK2701733T3 (da) Forbindelser til behandling af neuropsykiatriske forstyrrelser
DK2981255T3 (da) Terapeutiske anvendelser af empagliflozin
DK3626270T3 (da) Behandling af kardiovaskulære sygdomme
DK3054976T3 (da) Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose
DK2747763T3 (da) (bacterio-)chlorofyllfotosensibilisatorer til behandling af øjensygdomme og -lidelser
DK2897611T3 (da) Fremgangsmåder til behandling af hepatitis c
DK2961378T3 (da) Fremgangsmåder til behandlingen af mitochondrisk sygdom
HRP20181000T1 (hr) Postupci liječenja stanja povezanih s kosom
BR112013023142A2 (pt) método de tratamento de cabelos
DK2961426T3 (da) Behandling af sygdomme i centralnervesystemet ved intranasal indgivelse af immunoglobulin g
DK2892556T3 (da) Sammensætninger og fremgangsmåder til behandling af sygdomme
DK2900259T3 (da) Glycosidase-regime til behandling af infektionssygdomme
BR112014029487A2 (pt) método para o tratamento cosmético